<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31125276</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2378-9506</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of global oncology</Title>
          <ISOAbbreviation>J Glob Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>19</EndPage>
          <MedlinePgn>1-19</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">JGO.18.00173</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JGO.18.00173</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. We assessed the benefit of palbociclib plus letrozole in Asians.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS">Of 666 enrolled postmenopausal women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (no prior treatment of advanced disease), 95 were Asian. Patients were randomly assigned 2:1 to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was investigator-assessed PFS. Secondary end points were overall survival, objective response, patient-reported outcomes, pharmacokinetics, and safety.</AbstractText>
          <AbstractText Label="RESULTS">Median PFS was significantly longer in Asian patients who received palbociclib plus letrozole versus placebo plus letrozole (25.7 months [95% CI, 19.2 months to not estimable] <i>v</i> 13.9 months [95% CI, 7.4 to 22.0 months]; hazard ratio, 0.49; 95% CI, 0.27 to 0.87; <i>P</i> = .007). The most common toxicities with palbociclib were hematologic and more frequent among Asians versus non-Asians: neutropenia (any grade, 95.4% <i>v</i> 76.8%; grade 3/4, 89.2% <i>v</i> 62.5%), leukopenia (43.1% <i>v</i> 38.3%; 32.3% <i>v</i> 23.5%), and thrombocytopenia (27.7% <i>v</i> 13.5%; 4.6% <i>v</i> 1.1%). No Asians had febrile neutropenia. Discontinuation rates as a result of adverse events were similar among Asian and non-Asian patients who received palbociclib plus letrozole (10.8% and 9.5%). In Asians, quality of life (QOL) was maintained with no significant differences observed between treatments from baseline in breast cancer-specific QOL and general health status scores. Change from baseline in EuroQol five dimensions index scores was significantly higher with palbociclib plus letrozole (0.013 <i>v</i> -0.069; <i>P</i> = .0132). Geometric mean palbociclib trough concentration values were higher in Asians versus non-Asians (93.8 <i>v</i> 61.7 ng/mL).</AbstractText>
          <AbstractText Label="CONCLUSION">Consistent with the overall study population, the addition of palbociclib to letrozole significantly improved PFS in Asians. Hematologic toxicities were more frequent in Asians versus non-Asians but manageable with early dose modifications while maintaining QOL.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Im</LastName>
            <ForeName>Seock-Ah</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Seoul National Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mukai</LastName>
            <ForeName>Hirofumi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>National Cancer Center Hospital East, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>In Hae</ForeName>
            <Initials>IH</Initials>
            <AffiliationInfo>
              <Affiliation>National Cancer Center, Gyeonggi-do, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masuda</LastName>
            <ForeName>Norikazu</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>National Hospital Organization Osaka National Hospital, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Chikako</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sung-Bae</ForeName>
            <Initials>SB</Initials>
            <AffiliationInfo>
              <Affiliation>University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Im</LastName>
            <ForeName>Young-Hyuck</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohtani</LastName>
            <ForeName>Shoichiro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Hiroshima City Hospital, Hiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang Bartlett</LastName>
            <ForeName>Cynthia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer, Collegeville, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Dongrui R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer, La Jolla, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iyer</LastName>
            <ForeName>Shrividya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mori</LastName>
            <ForeName>Yuko</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Japan, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mori</LastName>
            <ForeName>Ave</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Srl, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gauthier</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Finn</LastName>
            <ForeName>Richard S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>David Geffen School of Medicine, Los Angeles, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toi</LastName>
            <ForeName>Masakazu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Kyoto University, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT01740427</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Glob Oncol</MedlineTA>
        <NlmUniqueID>101674751</NlmUniqueID>
        <ISSNLinking>2378-9506</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G9ZF61LE7G</RegistryNumber>
          <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jgo/site/misc/authors.html. SEOCK-AH IM: <b>Consulting or Advisory Role:</b> AstraZeneca, Novartis, Roche, Genentech, Eisai, Pfizer <b>Research Funding:</b> AstraZeneca, Pfizer <b>Travel, Accommodations, Expenses:</b> Novartis, Roche, Genentech, MSD Oncology <b>Other Relationship:</b> Roche HIROFUMI MUKAI: <b>Honoraria:</b> Astra Zeneca, Pfizer, Daiichi Sankyo, Taiho, Takeda, Novartis : <b>Research Funding:</b> Japanese government, Pfizer, Eisai, Daiichi Sankyo, Nippon Kayaku NORIKAZU MASUDA: <b>Leadership:</b> Japan Breast Cancer Research Group Association <b>Honoraria:</b> Chugai Pharma, AstraZeneca, Pfizer, Eisai, Eli Lilly Japan, Takeda Pharmaceuticals <b>Research Funding:</b> Chugai Pharma (Inst), AstraZeneca (Inst), Kyowa Hakko Kirin (Inst), MSD (Inst), Novartis (Inst), Pfizer (Inst), Eli Lilly (Inst), Daiichi Sankyo (Inst) CHIKAKO SHIMIZU: <b>Honoraria:</b> AstraZeneca, Kyowa Hakko Kirin, Chugai Pharma, Asuka Seiyaku, Taiho Pharmaceutical, Mochida Pharmaceutical <b>Consulting or Advisory Role:</b> Eli Lilly Japan, Pfizer, Eisai, AstraZeneca <b>Research Funding:</b> Eli Lilly, MSD, Chugai Pharma, Pfizer SUNG-BAE KIM: <b>Consulting or Advisory Role:</b> Novartis (Inst), Odonate Therapeutics (Inst), Enzychem Lifesciences (Inst), Eli Lilly (Inst) <b>Research Funding:</b> Novartis (Inst), Dongkook Pharma (Inst), Genzyme (Inst) SHOICHIRO OHTANI: <b>Honoraria:</b> Chugai Pharma, AstraZeneca, Pfizer, Eisai CYNTHIA HUANG BARTLETT: <b>Employment:</b> Pfizer <b>Stock and Other Ownership Interests:</b> Pfizer DONGRUI R. LU: <b>Employment:</b> Pfizer, Pfizer (I) <b>Stock and Other Ownership Interests:</b> Pfizer, Pfizer (I) SHRIVIDYA IYER: <b>Employment:</b> Pfizer <b>Stock and Other Ownership Interests:</b> Pfizer <b>Research Funding:</b> Pfizer <b>Travel, Accommodations, Expenses:</b> Pfizer YUKO MORI: <b>Employment:</b> Pfizer R&amp;D Japan <b>Stock and Other Ownership Interests:</b> Pfizer AVE MORI: <b>Employment:</b> Pfizer <b>Stock and Other Ownership Interests:</b> Pfizer ERIC GAUTHIER: <b>Employment:</b> Pfizer <b>Stock and Other Ownership Interests:</b> Pfizer <b>Travel, Accommodations, Expenses:</b> Pfizer RICHARD S. FINN: <b>Consulting or Advisory Role:</b> Pfizer, Bayer AG, Novartis, Bristol-Myers Squibb, Merck, Eisai, Eli Lilly, Genentech, Roche, AstraZeneca, Exelixis <b>Research Funding:</b> Pfizer (Inst), Bayer AG (Inst), Novartis (Inst), Eisai (Inst), Eli Lilly (Inst), Merck (Inst), Bristol-Myers Squibb (Inst), Roche (Inst), Genentech (Inst) <b>Expert Testimony:</b> Novartis MASAKAZU TOI: <b>Honoraria:</b> Novartis, MSD, Takeda Pharmaceuticals, AstraZeneca, Eisai, Genomic Health, Chugai Pharma, Taiho Pharmaceutical, Bayer AG, Eli Lilly, Daiichi Sankyo, Kyowa Hakko Kirin, C&amp;C Research Laboratories, Yakult, Sanofi, Shimadzu, Pfizer, Konica Minolta <b>Consulting or Advisory Role:</b> Daiichi Sankyo, Kyowa Hakko Kirin, Taiho Pharmaceutical <b>Speakers’ Bureau:</b> Pfizer, AstraZeneca, Eli Lilly <b>Research Funding:</b> Taiho Pharmaceutical, Chugai Pharma, Shimadzu (Inst), Astellas Pharma (Inst), AFI Technology, C&amp;C Research Laboratories, Japan Breast Cancer Research Group (Inst), Pfizer, Eisai, Daiichi Sankyo (Inst), AstraZeneca, Ono Pharmaceutical <b>Patents, Royalties, Other Intellectual Property:</b> JP 2017-143763WO2017/131162A1 (Inst), PCT/JP2016/004374 (Inst) <b>Travel, Accommodations, Expenses:</b> Genomic Health, Eli Lilly <b>Other Relationship:</b> Japan Breast Cancer Research Group, Kyoto Breast Cancer Research Network, Organization for Oncology and Translational Research No other potential conflicts of interest were reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31125276</ArticleId>
        <ArticleId IdType="pmc">PMC6550032</ArticleId>
        <ArticleId IdType="doi">10.1200/JGO.18.00173</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Torre LA, Bray F, Siegel RL, et al.  Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25651787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jemal A, Center MM, DeSantis C, et al.  Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20647400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung H, Rosenberg PS, Chen WQ, et al.  Female breast cancer incidence among Asian and Western populations: More similar than expected. J Natl Cancer Inst. 2015;107:djv107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4651040</ArticleId>
            <ArticleId IdType="pubmed">25868578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Crown JP, Lang I, et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 2015;16:25–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25524798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardoso F, Costa A, Norton L, et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol. 2014;25:1871–1888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4176456</ArticleId>
            <ArticleId IdType="pubmed">25234545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> National Comprehensive Cancer Network: Clinical practice guidelines in oncology (NCCN guidelines). Breast cancer. Version 2.2017.  https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Finn RS, Dering J, Conklin D, et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2790859</ArticleId>
            <ArticleId IdType="pubmed">19874578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwata H, Im SA, Masuda N, et al.  PALOMA-3: Phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy—Safety and efficacy in Asian patients. J Glob Oncol. 2017;3:289–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5560465</ArticleId>
            <ArticleId IdType="pubmed">28831437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Martin M, Rugo HS, et al.  Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27959613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swain SM, Im YH, Im SA, et al.  Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: Results from the phase III trial CLEOPATRA. Oncologist. 2014;19:693–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4077449</ArticleId>
            <ArticleId IdType="pubmed">24869931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu B, Zhang XQ, Chi HD, et al.  Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: A retrospective comparison of East Asian and global studies. Asia Pac J Clin Oncol. 2014;10:330–339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24175966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma S, Bartlett CH, Schnell P, et al.  Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: Detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3) Oncologist. 2016;21:1165–1175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5061543</ArticleId>
            <ArticleId IdType="pubmed">27368881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenhauer EA, Therasse P, Bogaerts J, et al.  New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19097774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Pfizer: 2015 Annual Review: Advances in Oncology.  https://www.pfizer.com/files/investors/financial_reports/annual_reports/2015/assets/pdfs/pfi2015ar-advances-in-oncology.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Cristofanilli M, Turner NC, Bondarenko I, et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26947331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Diéras V, Harbeck N, Joy AA, et al: PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L). Ann Oncol 28:v74-v-108, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation> Yap YS, Tseng LM, Blackwell KL, et al: First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2. Ann Oncol 27, 2016 (suppl; abstr LBA1)</Citation>
        </Reference>
        <Reference>
          <Citation> Toi M, Huang C, Im YH, et al: MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy. Ann Oncol 28:x26-x34, 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28580882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> Yap YS, Suarez-Vizcarra J, Liu X, et al: Phase Ib study of ribociclib + letrozole in Asian non-Japanese patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESASIA. Cancer Res 78, 2018 (suppl; abstr P5-21-28)</Citation>
        </Reference>
        <Reference>
          <Citation> Masuda N, Inoue K, Nakamura R, et al: Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. Int J Clin Oncol, 24:262-273, 2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6399170</ArticleId>
            <ArticleId IdType="pubmed">30392115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda N, Nishimura R, Takahashi M, et al.  Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. Cancer Sci. 2018;109:803–813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834809</ArticleId>
            <ArticleId IdType="pubmed">29345736</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
